Pain Therapeutics, Inc. (PTIE) Reached 1-Year Low on Jun, 29

June 29, 2018 - By Samuel McNeil

A yearly low was reached by Pain Therapeutics, Inc. (NASDAQ:PTIE). Today’s price per share was $2.15. It’s 5.00 % below our $2.04. The yearly low was published on Jun, 29 by Barchart.com. The company has $14.83M MC. At $2.04 stock price target, the company valuation changes by $741,250 less.

PTIE is reaching $2.15 during the last trading session, after decreased 4.66%.Pain Therapeutics, Inc. has 215,441 shares volume, 82.23% up from normal. PTIE is uptrending and has moved 133.72% since June 29, 2017. The stock outperformed the S&P 500 by 121.15%.

For more Pain Therapeutics, Inc. (NASDAQ:PTIE) news posted briefly go to: Nasdaq.com, Benzinga.com, Benzinga.com, Schaeffersresearch.com or Benzinga.com. The titles are as follows: “Mid-Afternoon Market Update: US Stocks Turn Negative; Cara Therapeutics Shares Spike Higher” posted on June 27, 2018, “20 Stocks Moving In Thursday’s Pre-Market Session” on June 28, 2018, “23 Stocks Moving In Wednesday’s Pre-Market Session” with a publish date: June 27, 2018, “3 Stocks Sinking in Afternoon Trading” and the last “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” with publication date: June 28, 2018.

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States.The firm is worth $14.83 million. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain.Currently it has negative earnings. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood diagnostic/biomarker to detect Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: